文献速递甲状腺疾病垂体与肾上腺疾病

先天性甲状腺功能减退症神经发育与生长评估:408例患者6年系列随访研究

Assessment of Neurodevelopment and Growth in Congenital Hypothyroidism: Serial 6-Year Follow-up Study of 408 Patients.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

基于全国数据库对919 707名儿童进行纵向分析,其中先天性甲状腺功能减退症(CH)患病率为0.05%(n=408)。与对照组相比,CH组疑似神经发育障碍风险更高(倾向评分加权OR 4.52;95%CI 2.91, 7.02),5个K-ASQ域风险均显著增加,且低年龄别身高z评分风险更高,但BMI年龄别z评分升高风险无显著差异。延迟用药与更差神经发育结局相关。

要点

  • CH组疑似神经发育障碍风险显著高于对照组(加权OR 4.52;95%CI 2.91, 7.02)。
  • CH组在5个K-ASQ域风险均显著增加,神经发育评估时间无交互作用(交互P均>.05)。
  • CH组低身高别年龄z评分风险更高,但BMI别年龄z评分升高风险无显著差异。

核心结论

  • CH组神经发育结局更差且年龄别身高z评分降低,治疗开始越延迟结局越差。

研究设计与样本

  • 利用全国数据库对919 707名儿童进行纵向分析,CH暴露采用理赔数据识别,按1:10比例随机匹配病例与对照后采用逆概率治疗加权和广义估计方程模型分析。

主要发现

  • CH患病率为0.05%(n=408)。
  • 与对照组相比,CH组疑似神经发育障碍风险更高(倾向评分加权OR 4.52;95%CI 2.91, 7.02)。
  • CH组在5个K-ASQ域风险均显著增加。
  • 根据神经发育评估时间,各轮次均未见时间交互作用(交互P均>.05)。
  • CH组低年龄别身高z评分风险更高,但BMI年龄别z评分升高风险无显著差异。

关键数值与推荐

  • 主要结局为疑似神经发育障碍,采用韩国年龄与发育进程问卷(K-ASQ)从9至72月龄每年评估。
  • 次要结局为身高和BMI z评分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The link between congenital hypothyroidism (CH) and neurodevelopment is suggested, yet studies applying quantifiable measures are lacking. Moreover, socioeconomic disparities and subtle variation in timing of approach make the relationship difficult to detect. OBJECTIVE: To evaluate associations between CH and abnormalities in neurodevelopment and growth and determine the critical period for intervention. METHODS: We utilized a nationwide database to conduct a longitudinal analysis of 919 707 children. Exposure to CH was identified using claims-based data. The primary outcome of interest was suspected neurodevelopmental disorder, as measured using the Korean Ages & Stages Questionnaires (K-ASQ) administered annually from 9 to 72 months of age. Secondary outcomes were height and BMI z-scores. After randomly matching cases and controls at a 1:10 ratio, we employed inverse probability of treatment weighting and generalized estimating equation models for our analyses. We conducted subgroup analysis based on the age of treatment initiation. RESULTS: The prevalence of CH in our population was 0.05% (n = 408). Relative to the control group, the CH group had higher risk of suspected neurodevelopmental disorders (propensity score-weighted odds ratio: 4.52; 95% CI: 2.91, 7.02), and significantly increased risk in each of the 5 K-ASQ domains. No time interactions were noted at any rounds for the outcomes according to when the neurodevelopmental assessment was conducted (all P for interaction >.05). The CH group also had higher risk for low height-for-age z-score, but not for elevated BMI-for-age z-score. In subgroup analysis, delayed medication for CH correlated with worse neurodevelopmental outcomes. CONCLUSION: The CH group had worse neurodevelopmental outcomes and reduced height-for-age z-score. Outcomes were worse when onset of treatment was increasingly delayed.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ha EK, Kim JH, Cha HR, et al. Assessment of Neurodevelopment and Growth in Congenital Hypothyroidism: Serial 6-Year Follow-up Study of 408 Patients. J Clin Endocrinol Metab. 2023. PMID: 37335967. doi:10.1210/clinem/dgad364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。